---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-049197"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:24:22.502214+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics FY 2023 net loss $34.1M; cash into Q4 2025; SNS-101 data due Q2 2024

## Summary
- Net loss $34.1M in FY2023 vs $48.6M in FY2022; R&D expense fell to $18.3M from $30.4M.
- Cash, equivalents, and marketable securities $65.8M at Dec 31, 2023 (down from $107.1M); runway now into Q4 2025.
- SNS-101 Phase 1/2: topline efficacy/biomarker data expected Q2 2024 (ahead of prior guidance); no DLTs in 33 patients.
- Resource realignment: paused preclinical TMAb programs (SNS-102, SNS-103, SNS-201) to focus on SNS-101.
- Appointed Ron Weitzman as part-time CMO (Jan 2024) and Stephanie Krebs as CBO (Nov 2023).

## SEC filing metadata
- accession: 0001193125-24-049197
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312524049197/0001193125-24-049197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312524049197/d770175d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-049197
- JSON: https://secwatch.observer/filing/0001193125-24-049197.json
- Plain text: https://secwatch.observer/filing/0001193125-24-049197.txt

## Key facts
- Earnings Releases
  Sensei Biotherapeutics, Inc. reported financial results for full year ended December 31, 2023.
  - Period: full year ended December 31, 2023
  - Result: reported results
  source text: On February 28, 2024, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312524049197/0001193125-24-049197-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.